← Back

Wire · opportunities

FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA

Published

11 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at patientcareonline.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The FDA approved Asundexian, the first factor XIa inhibitor, to reduce stroke risk in adults after a recent mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA, as an addition to antiplatelet therapy. The approval follows a phase 3 trial showing a 26% relative reduction in ischemic stroke risk but highlights caution due to increased bleeding risks in older adults and early treatment phases.

This Wire brief sits within Fusion42's coverage of Medtech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You must adjust your stroke prevention product plans to include factor XIa inhibition as a new adjunctive therapy. Older patient safety concerns open space for alternatives with better bleeding profiles.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalstroke-preventionasundexianfactor-xia-inhibitorbleeding-risk